Objective: Current data on primary aldosteronism (PA) from Asian populations are scarce. This cohort study clarifies the attributes of patients with PA in a typical Chinese population. Design: An observational cohort study. Methods: The records of patients referred to the Hypertension Clinic from a multi-centre registration in Taiwan from January 1995 to December 2007 were reviewed. All patients with PA were classified into two subtypes: aldosteroneproducing adenomas (APA) and idiopathic hyperaldosteronism (IHA); their characteristics were compared. Results: Our cohort consisted of 346 patients with PA, 255 with APA and 91 with IHA. The initial hypokalaemia (59% in APA vs. 27.5% in IHA, p < 0.0001) and transtubular potassium gradient (TTKG) (6.30 ± 2.41 in APA vs. 4.91 ± 2.03 in IHA, p = 0.01) were higher in the APA group. Baseline plasma aldosterone concentration (PAC) was also significantly different between the two subgroups (49.96 ± 38.15 ng/dl in APA vs. 34.24 ± 21.47 in IHA, p < 0.0001). Conclusions: In typical Chinese PA patients, the APA subgroup had a higher proportion of hypokalaemia with elevated TTKG and higher PAC as compared with the IHA subgroup. This largest Asian database also demonstrated major differences between the Caucasian and Chinese populations including female predilection, frequent hypokalaemia, and common paralytic myopathy.
Introduction
Numerous recent reports have examined the prevalence and characteristics of patients with primary aldosteronism (PA), given that PA is now considered a common cause of hypertension and that most patients are normokalaemic at presentation. 1, 2 In recently published data, the overall prevalence of PA is 11.2% among newly diagnosed hypertensive patients referred to tertiary centres, of whom 4.8% had curable aldosterone-producing adenomas (APA). 3 The potential curability and prevention of excessive cardiovascular damage and events also underscore the need for developing accurate strategies for the timely diagnosis of PA. 4 However, 50 years after the American endocrinologist Jerome W Conn described the syndrome in 1955, 5 most conclusions are still derived from Caucasian populations, while data from Asian populations are scarce. 6, 7 Among the various ethnic populations, some atypical presentations of PA have been reported, 8, 9 implying that genetic background produces a possible phenotypic effect. Our observational, multi-centre study attempts to clarify the characteristics of patients with PA in a typical Chinese population.
Subjects and methods Patients
Data source. From January 1995 to December 2007, the records of patients screened at or referred to the Hypertension Clinic of the National Taiwan University Hospital and its affiliated hospitals were reviewed for this observational cohort study investigating PA. All data were recorded in the Taiwan Primary Aldosteronism Investigation (TAIPAI) database. The database was constructed for quality assurance in one medical centre (National Taiwan University Hospital, Taipei, Taiwan) and its three branch hospitals in different cities (National Taiwan University Hospital Yun-Lin branch, Yun-Lin, southern Taiwan; En Chu Kong Hospital, Taipei County; and Tao-Yuan General Hospital, Tao-Yuan, central Taiwan). A total of 346 patients were diagnosed with PA during the period from January 1995 to December 2007.
Informed consent was waived because there was no breach of privacy and the study did not interfere with clinical decisions related to patient care. The Institutional Review Board of National Taiwan University Hospital (Taipei, Taiwan) approved this study.
Data collection. All anti-hypertensive medications were discontinued for at least 21 days before the PA investigation, except for calcium antagonists or alpha-blockers when required. [10] [11] [12] Medications that might interfere with the renin-aldosterone axis, such as steroids, sex hormones, liquorice, or non-steroidal anti-inflammatory drugs, were also withheld for at least 6 weeks. The patients consumed a normal diet, with salt ad libitum. Biochemical data were collected on arrival for the aldosterone study. The patients were also supplied with potassium during the testing period if hypokalaemia was identified. All blood samples for biochemical analysis (plasma aldosterone concentration (PAC) and plasma renin activity (PRA)) were collected from subjects in a seated position after an overnight fast and a 1-h rest. Patients' associated diseases were recorded based on the scoring system proposed by Charlson et al., 13 a weighted index that takes into account the number and severity of the comorbidities.
Screening of primary aldosteronism. The initial evaluation included: 1) Age < 35 years at the time of presentation of hypokalaemia or hypertension; 2) difficult-to-control hypertension after therapy initiation; 3) the clinical occurrence of a hypertensive crisis; 4) the presence of hypokalaemia or metabolic alkalosis, or a random aldosterone-renin ratio (ARR) > 1259 ng L -1 per ng L -1 s -1 ; and 5) evidence of adrenal incidentaloma with hypertension or hypokalaemia. If any of the above criteria is fulfilled, the standard screening protocol of PA would be followed (figure 1). Difficultto-control hypertension was defined as patients taking more than three anti-hypertensive medications while their blood pressure (BP) still failed to reach their therapeutic target. 14 Hypertensive crises are characterised by severely elevated BP, usually higher than 180/110 mmHg, along with progressive or impending target organ damage. 15 In this study, end-organ damage with an elevated diastolic BP higher than 120 mmHg was defined as a hypertensive crisis in concordance with the current guideline. 16 After a positive screening test result, a confirmatory test was conducted to establish the diagnosis of primary aldosteronism (PA) (figure 2). The ethnic composition of our cohort reflected a typical Chinese population.
Confirmation of primary aldosteronism. Among the study population, 346 patients had undergone either captopril or saline loading tests as previously reported. 10, 11 Blood samples for PAC and PRA were obtained before and 1.5 h after the administration of 50 mg of captopril. 10 An ARR > 1259 ng L -1 per ng L -1 s -1 with PAC > 100 ng L -1 (> 277 pmol L -1 ) after the administration of captopril 11 was defined as a positive test for PA. We selected an ARR > 1259 ng L -1 per ng L -1 s -1 because this value had the best sensitivity and specificity to differentiate PA from essential hypertension in the TAIPAI database. 10, 11 In addition, patients who were categorised as having essential hypertension but had low PRA (< 0.056 ng L -1 s -1 ) after an appropriate drug washout period underwent saline infusion tests.
The patients who underwent saline infusion also followed the standard protocol. Briefly, after lying supine for at least 30 min, 2 liters of 0.9% NaCl solution were administered intravenously from 8:00 to 12:00 am. Blood samples for PAC were drawn before and at the end of the saline infusion. After salt loading, a PAC > 100 ng L -1 indicated PA. 10 
Differential subtyping of primary aldosteronism
Imaging studies. A computerised tomography (CT) scan of the adrenal glands with a non-ionic iodinated contrast agent was done on all the PA patients, with at least 3 mm contiguous slices in a normal surrounding. Although there were no strict measurements of normal adrenal size, CT imaging was considered abnormal when any volume thicker than 10 mm 3 was detected. Those with inconclusive CT findings underwent dexamethasone suppression adrenocortical scintigraphy with CT (NP-59, I-131 -6-beta-iodomethyl-19-norcholesterol & NP59-SPECT/CT). 17 Adrenal venous sampling. Bilateral adrenal venous sampling (AVS) was required for patients older than 40 years and equivocal results on adrenal CT encountered after 2002. Successful venous cannulation was defined as the ratio of the cortisol level of the adrenal vein to that of the inferior vena cava > 3. Lateralisation of aldosterone secretion was defined by a greater than four-fold difference in the aldosterone/cortisol ratio between the two adrenal glands. Before 2002, the criteria to diagnose APA were predominantly based on imaging and histopathological studies, e.g., adrenal CT and NP59, PRA, serum potassium, and post-therapeutic response after an adrenalectomy or anti-aldosterone agent use.
In the differential subtyping protocol, if the patients had a clear unilateral adrenal tumour (> 10 mm 3 ) and were older than 40 years, AVS was performed to exclude a possible incidentaloma (non-functioning adenoma). Otherwise, in younger population (age < 40 years), patients would directly undergo adrenalectomy. For patients with negative results in adrenal CT imaging, AVS was routinely performed. However, for patients who refused AVS, had equivocal findings on AVS, or had unsuccessful AVS procedures, NP-59 SPECT/CT adrenal scintigraphy was given to detect possible lateralisation (figure 3).
Additional tests
The estimated glomerular filtration rate (eGFR) was calculated using the modified Modification Diet in Renal Disease (MDRD) formula and was proportioned to 1.73 m 2 of the body surface area. 18 Renal impairment was categorised based on an eGFR < 60 ml/min per 1.73 m 2 . These categories were modified from the National Kidney Foundation cut-off points for mild kidney damage. 19 Among the study population, 91 patients had an appropriate transtubular potassium gradient (TTKG) measurement done when the confirmatory ARR was performed after an adequate medication washout period. Urine and blood potassium, as well as osmolality were obtained for the TTKG. The formula of the TTKG = (urine potassium × serum osmolality)/(serum potassium × urine osmolality). Calculation of the TTKG required that urine Na + be > 25 mEq/L and that urine osmolality be no less than the plasma osmolality. 20 
Measurement of aldosterone and renin
The concentration of aldosterone was measured by radioimmunoassay (RIA) using commercial kits (Aldosterone MAIA Kit, Biochem ImmunoSystems, Bologna, Italy) as previously described. 6, 21 The detection limit was 10.0 ng L -1 with a 90% confidence interval, with the normal range of 35-300 ng L -1 in an upright position. PRA was measured as the generation of angiotensin I in vitro using a commercially available RIA kit (Incstar Corporation, Stillwater, Minnesota, US). Its normal range was 0.73 ± 0.37 ng L -1 s -1 in an upright position. In our three centres over a period of 12 years, the same aldosterone and renin assays were used.
Adrenalectomy
All operations were performed by a single experienced laparoscopic surgeon, using the lateral transperitoneal approach to ensure that the principles of adrenal gland surgery were strictly followed. 22 
Histopathological studies
All of the surgically removed adenomas were re-evaluated by a histopathologist in the TAIPAI study group who was blind to the clinical data. A histological diagnosis of APA was based on well-defined, encapsulated tumours, predominantly consisting of foamy clear cells. 23 Adenoma appeared as nodules of clear cells in sheets or nests that were sharply demarcated by a pseudo-capsule and compressed the nonneoplastic, uninvolved adrenal gland. 24 Adenomas were differentiated from nodular adrenal hyperplasia by their solitary and well-circumscribed nature. 24, 25 Adrenal glands from the patients with idiopathic hyperaldosteronism (IHA) were marked by diffuse hyperplasia of cells resembling those of normal zona glomerulosa with or without macroor micro-nodules. 12 
Diagnostic criteria
Identification of APA in hypertensive patients required all of the following 'modified 4 corners score' criteria: 11,12,26 1) evidence of autonomous excess aldosterone production based on an ARR > 1259 ng L -1 per ng L -1 s -1 after captopril, and a post-saline loading PAC > 100 ng L -1 or urine aldosterone ≥ 12 μg/24 h (the current recommendation for diagnosis of PA); 27 2) CT scan showing evidence of an adenoma; 3) lateralisation of aldosterone secretion at the AVS or during the dexamethasone suppression NP-59 SPECT/CT; 17 and 4) pathologically proven adenoma after an adrenalectomy, and cure of hypertension without anti-hypertensive agents or improved hypertension, potassium, PAC, and PRA as described. 26 IHA was established based on the following criteria: 10 1) evidence of autonomous excess aldosterone production based on an ARR > 1259 ng L -1 per ng L -1 s -1 after captopril or salt loading, and a post-saline loading PAC > 100 ng L -1 or urine aldosterone ≥ 12 μg/24 h; 2) CT scan showing evidence of bilateral diffuse enlargement; 3) non-lateralisation of aldosterone secretion at the AVS, or after the dexamethasone suppression adreno-cortical scintigraphy; 17 and 4) evidence of diffuse cell hyperplasia in the pathology studies.
In patients with negative captopril tests, the pre-specified ARR < 1259 ng L -1 per ng L -1 s -1 and PAC < 250 ng L -1 , and a negative salt loading test were considered to be diagnostic of essential hypertension. The protocol of the TAIPAI study group is summarised in figures 1-3.
Identification of glucocorticoid remediable aldosteronism
Genetic analysis by long polymerase chain reaction (PCR) in search of the chimeric CYP11B1/CYP11B2 gene was performed on patients with a family history of high ARRs as previously reported. 28 In the long PCR, DNA from all subjects (positive control, negative control, patients with PA or essential hypertension) was amplified with a pair of primers specific for the aldosterone synthase gene (CYP11B2). Only DNA from the patients with glucocorticoid remediable aldosteronism (GRA) (positive control) produced a 3.9-kb fragment when a pair of sense primers for the 11-hydroxylase gene and antisense primers of the aldosterone synthase gene was used for amplification. The results have also been sent to the international GRA registry for further confirmation (www.brighamandwomens.org/gra). 28 The improvement rate of hypertension in PA A hypertension cure or improvement rate was defined by a normalised BP level without the use of anti-hypertensive medication, or when the BP could be better controlled (at least at the patient's baseline) with a lower demand for antihypertensive medications. 12 
Statistical analysis
All evaluated parameters were expressed as mean ± SD or median (25 th to 75 th percentile), where appropriate. Normal distribution of various parameters was investigated. All of the data analyses were performed with SPSS for Windows, version 12.0 (SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was considered statistically significant.
Results

Baseline clinical characteristics
The cohort subtypes consisted of 255 APA patients and 91 IHA patients. Demographic data showed a female predilection (58%) and mean age at disease diagnosis of 48.6 ± 11.8 years. The mean presenting systolic BP was 152.9 ± 23.0 mmHg and the diastolic BP was 93.7 ± 15.2 mmHg. Fourteen (4%) patients had normal BP when the diagnosis of PA was made, and five patients had hypertension when they were pregnant. The mean duration between the onset of hypertension and diagnosis was 7.2 years. The mean body mass index (BMI) was 25.1 ± 4.0 kg/m 2 , while the average estimated renal function as calculated by the MDRD formula was 99.2 ml/min. We identified three families with GRA in this database because of their family history of hypokalaemia. The three most prevalent comorbidities were left ventricular hypertrophy (17.6%), diabetes mellitus (12.1%), and chronic hepatitis B infection (8.7%), reflecting the typical Taiwanese population (an HBV-endemic area). 29 The average Charlson score was 1.36. The annual detection rate at our institution increased from 7. 
Initial presentations and pharmacotherapy for hypertension
Aside from the most common presentations of hypertension, hypokalaemia (50 %) was the second-most frequent initial presentation in this cohort. Other presentations included paralysis (11.5%), incidentaloma (4.3%), and rhabdomyolysis (2.3%). Other rare presentations were pregnancy-related hypertension (1.4%), intracranial haemorrhage (0.6%), and seizure (0.6%), as seen in table 1. Some 25 patients (7.2%) had advanced chronic renal disease (eGFR < 60 ml/min per 1.73 m 2 ) when PA was noted.
In total, 96% of the patients received pharmacotherapy for hypertension as follows: calcium channel blockers (66.7%), beta-adrenergic blockers (45%), spironolactone (44.6%), angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (28.6%), alpha-adrenergic blockers (25.5%), and diuretics (6%). The majority (68.6%) of the patients in the TAIPAI database were taking at least two drugs, while 17.3% took only one. The remaining 14.1% of patients did not take any anti-hypertensive medication even though their BP was high. BP in patients taking spironolactone did not differ significantly from that among non-spironolactone users (mean arterial BP in spironolactone users 113.43 ± 16.82 mmHg versus non-spironolactone users 114.11 ± 16.48 mmHg, p = 0.722). The mean dose of spironolactone at baseline was 50 mg daily in our Chinese patients. The mean serum potassium levels at the entry of study were also not different between the two groups (mean potassium level in spironolactone users 3.37 ± 0.74 mmol/L versus non-spironolactone users 3.35 ± 0.82 mmol/L, p = 0.86). The ARR in the spironolactone group after a 3-week washout period increased significantly in our database from 7267.8 ± 3282.9 to 23254.1 ± 24496.0 ng L -1 per ng L -1 s -1 , p = 0.0473.
Confirmatory and subtype studies
A total of 332 patients received the captopril test and 110 patients received the saline infusion test. Urinary aldosterone was used to confirm PA in 190 patients. There were 20 patients with divergent results between the captopril and saline infusion tests. Half of them revealed aldosterone suppression on the captopril test. The PA was confirmed by one of the tests yielding loss of aldosterone suppression. A total of 70 patients underwent AVS with a success rate of 54%, while 27 patients received NP59-SPECT/CT 17 . Among the eight patients who between the two subgroups with respect to age, duration of hypertension, presenting BP, BMI, daily sodium excretion, and serum creatinine. However, the initial presentation of hypokalaemia was more frequent in APA patients (59% in APA vs. 27.5% in IHA, p < 0.001). The TTKG was also higher in the APA patients than in the IHA patients (6.30± 2.41 vs. 4.91±2.03, p = 0.01) (table 2) . In addition, after the anti-hypertensive medication was held for 3 weeks, the PAC level of the APA group before the confirmatory tests, including the captopril and saline loading tests, was significantly higher (table 3) . There were three families identified with familial hyperaldosteronism type I, by the presence of a chimeric gene originating from an unequal cross-over between the CYP11B1 and CYP11B2 genes.
Treatment
Some 71.7% of the APA (183/255) and 16.5% (15/91) of the IHA patients received adrenalectomies. Unilateral nodular hyperplasia was noted on the abdominal CTs of 15 of the IHA patients and required an adrenalectomy. Recent evidence has suggested that a partial adrenalectomy may benefit patients with IHA. 30 In the APA adrenalectomy group, 15 patients underwent partial adrenalectomies, and one had a local alcohol injection due to an abdominal aortic aneurysm, which prevented possible surgical intervention. The hypertension cure or improvement rate was 77% in the APA group and 26.7% in the IHA group. The mean BP of PA declined from a baseline 113.05 ± 17.5 mmHg to 100.65 ± 14.89 mmHg after treatment. received AVS and NP59-SPECT/CT concomitantly, NP59-SPECT/CT led to one negative adenoma identification and two adenomas in patients with negative lateralisation results on AVS. A comparison of patients with APA vs. IHA (table 2) revealed no significant differences Abbreviations: APA, aldosterone-producing adenoma; IHA, idiopathic hyperaldosteronism; PAC, plasma aldosterone concentration; PRA, plasma renin activity *Data are expressed as mean ± standard deviation (SD).
Discussion
Once thought to be an extremely rare disease, PA was initially observed in 1955 by Conn 5 and has become prevalent following the development of the ARR screening test proposed by Hiramatsu in 1981. 31 In recent studies, it has accounted for 5-10% of all hypertensive patients, and some have even suggested that PA may be the most common secondary cause of hypertension. 32 In our database, the annual identified number of PA cases has increased from 7.43 (1995-2001) to 49 (2002-2007) because of better recognition and awareness. In this first, large validation study of the Chinese population, the female predilection is different from the male tendency observed in the previous studies based on Caucasian populations. 3, [33] [34] This study also demonstrated a higher proportion of patients with hypokalaemia as the initial presentation (60.4%), in contrast to recently published data that most PA patients are normokalaemic. 1, 6, 35 However, after applying the ARR screening method routinely in TAIPAI group, earlier diagnosis of PA has become possible, as has been the experience of other countries. 1 The normokalaemia of PA has become dominant after ARR screening began in the 1990s. 1 Blumenfeld et al. have pointed out that IHA patients are younger and more frequently normokalaemic than APA patients. 36 In the current study, the pathogenesis of the disease subtype is also associated with the serum potassium level and the capacity for urinary potassium excretion. The capacity for aldosterone secretion is higher in patients with APA and leads to a higher proportion of hypokalaemia.
In the comorbidities analysis, the occurrence of chronic kidney disease among PA patients (7.2%) is less than that of the general Chinese population (12%). 37 Whether the phenomenon of renal hyperfiltration in PA, pointed out by several reports, 34, 38 eventually leads to permanent renal damage is still controversial. However, in the article by Ribstein et al., the renal function of PA patients after adrenalectomy was lower than the baseline renal function. 38 Consequently, the actual prevalence of chronic kidney disease in the PA population may be masked by the phenomenon of hyperfiltration as shown in this study. To elucidate the relationship between hyperfiltration and permanent renal damage, Reincke et al. matched post-surgical PA patients with control hypertension patients to provide a more accurate perspective. They pointed out that effective treatment of mineralocorticoid excess removes renal hyperfiltration and may uncover the real extent of renal damage associated with PA. 39 In the TAIPAI group, the improvement rate in BP by adrenalectomy in the APA group is 77% (137/178), comparable with findings in previous studies. 40 Four female patients have been diagnosed with PA upon presenting with gestational hypertension, causing one patient to terminate her pregnancy. Three GRA families (0.9% in the present cohort) were identified. This autosomal dominant monogenic form of aldosteronism is thought to account for only 0.5-1.0% of PA cases. 41 However, the actual prevalence of GRA in Chinese population, either in the high-risk group of individuals with primary hyperaldosteronism or in the general population, remains to be established in future research.
To separate the two major subtypes of PA, the current gold standard is AVS, which has been adopted in our study group since 2002. 42 Unlike the Western populations where IHA is the dominant pattern, APA is the more frequent subtype at diagnosis in TAIPAI database. 43 Furthermore, IHA patients present with normokalaemia more frequently and have lower TTKG values than APA patients. The serum aldosterone level is also significantly higher in APA patients. Circulating aldosterone may have a dose-dependent effect on renal collecting tubules, thereby causing additional renal potassium loss. Consequently, a TTKG may help clinicians predict the disease pattern. In the IHA group with relatively higher TTKGs, AVS should be used to exclude the possibility of micro-APA or unilateral nodular hyperplasia. Recently, a cheaper and faster initial screening tool has been developed using the ratio of serum sodium to urinary sodium to (serum potassium) 2 to urinary potassium (SUSPPUP) which is also based on the renal tubular characteristics of PA. 44 The application of ARR to a greater number of hypertensive patients has led to a 5-to 15-fold increase in the identification of patients affected by PA. 1 A decreasing prevalence of APA and increasing prevalence of IHA has been noted previously 4 and has been corroborated in our study, where the prevalence of APA decreased from 76% to 62%. (See figure 5) . The use of ARR now includes more IHA patients, who may have been normokalaemic and, therefore, undiagnosed by traditional criteria. Conversely, the ARR criteria may be overestimating IHA by misclassifying other aetiologies of non-PA hypertension, such as low-renin hypertension (LRH), into the category of IHA. 45 Consequently, routine AVS or NP59-SPECT/CT offers a decisive diagnosis and avoids possible overestimation of IHA.
Study limitations
As a large cohort representing the typical Chinese population, this study still suffers from some inherent limitations. First, a retrospective study would have a bias on case selection. Referral and post-referral selection bias would have played a major role in determining the characteristics of our patients. For example, the study consisted of patients 'referred for investigation of PA', and hence would have included more florid, 'classic' varieties of PA. Since a high ARR with a CT-confirmed adenoma is more easily identified by general practitioners, the patients were referred to our affiliated hospitals for further confirmation. Following the referral, it appears that only patients with certain characteristics (such as age < 35 years, resistant hypertension, hypokalaemia, incidentaloma, etc.) underwent further Figure 5 . A decreasing prevalence of APA and increasing prevalence of IHA has been noted universally in many countries after adopting the aldosterone/renin ratio as a standard PA screening method for suspected secondary hypertension (grey zone). Conventional practice means that the clinician raised the index of suspicion for PA until patients have both resistant hypertension and hypokalaemia. APA, aldosterone-producing adenomas; IHA, idiopathic hyperaldosteronism.
testing for PA. This may partly explain the high prevalence of APA, whereas most other recent studies have observed a preponderance of IHA. Second, the awareness of the general practitioners may have changed during the 12 years of the study, suggesting that the differences may not be entirely due to different screening strategies. Third, definite differentiation between APA and IHA was based on imaging studies, and not all enrolled PA patients received AVS.
Conclusion
In summary, this Chinese cohort of PA has the advantage of being the largest patient sample in Asia. This cohort has demonstrated three main demographic differences as compared with the Caucasian population, including female predilection, more frequent hypokalaemia, and paralytic myopathy. The association between the amount of circulating aldosterone and the strength of the TTKG elucidates the clinical spectrum of PA and warrants further clarification in future research.
